Litcius/Paper detail

Pembrolizumab for Microsatellite-Instability–High Advanced Colorectal Cancer

David H. Ilson

2020Journal watch172 citationsDOI

Abstract

Single-agent therapy and combination immune checkpoint inhibitor therapy are now approved for microsatellite-instability (MSI)–high colorectal cancer

Topics & Concepts

Microsatellite instabilityPembrolizumabMedicineColorectal cancerCancerOncologyInternal medicineMicrosatelliteGeneticsBiologyImmunotherapyGeneAlleleGenetic factors in colorectal cancerColorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers
Pembrolizumab for Microsatellite-Instability–High Advanced Colorectal Cancer | Litcius